{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for lactic root_notes_note in Note (approximate match)
Status:
Investigational
Source:
INN:nafcaproic acid [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Nafcaproic acid (DA-808) is a synthetic choleretic agent.
Status:
Investigational
Source:
NCT04205227: Phase 1/Phase 2 Interventional Active, not recruiting Cancer
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02423577: Phase 2 Interventional Completed Influenza
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02561091: Phase 3 Interventional Completed Hearing Loss
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
XG-102 (also known as brimapitide), a D-stereoisomer of a c-Jun-N-terminal kinase-1111 was developed in a biocompatible gel formulation for the treatment of sudden sensorineural hearing loss with a single-dose administration into the middle ear. It’s a cell-penetrating peptide which inhibits the JNK stress kinase. JNK is activated following various types of cochlear insults (stress) that cause acute inner ear hearing loss and plays a key role in apoptosis of sensory cells as well as in inflammatory responses. By blocking JNK, AM-111 protects stress-injured cochlear cells and helps to prevent or reduce chronic hearing loss. Auris Medical's otoprotective drug AM-111 has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the treatment of acute sensorineural hearing loss (ASNHL), a condition which may occur following various inner ear injuries. In addition, XG-102 was studied in phase III clinical trials in the treatment of acute inner ear hearing loss and in the reduction of post-cataract surgery intraocular inflammation. Besides, XG-102 is advancing through pre-clinical development with programs in ocular inflammation, urology, nephrology and Alzheimer’s disease.
Status:
Investigational
Source:
NCT03502967: Early Phase 1 Interventional Enrolling by invitation Traumatic Brain Injury
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03013998: Phase 1/Phase 2 Interventional Recruiting Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01225536: Phase 1 Interventional Completed Solid Tumor
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02907073: Phase 1/Phase 2 Interventional Terminated Myeloma
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT02592824: Phase 3 Interventional Completed Coronary Artery Bypass Surgery
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00454233: Phase 2 Interventional Completed Diabetes Mellitus Type 2
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
ASP-543 (also known as YM-543), a selective inhibitor of the sodium-glucose cotransporter 2. This protein is specifically expressed in the kidney that plays an important role in renal glucose reabsorption, and its inhibition may present a novel therapeutic strategy for treating diabetes. ASP-543 participated in phase II clinical trials in Europe and in the USA for the treatment of Type 2 diabetes mellitus but these studies were discontinued.
